Norvasc — Net Sales
Viatris Norvasc — Net Sales increased by 19.9% to $210.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.9%, from $172.30M to $210.00M. Over 4 years (FY 2021 to FY 2025), Norvasc — Net Sales shows a downward trend with a -3.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong brand loyalty or successful market penetration in key regions, while a decrease may indicate increased generic competition or a shift in prescribing patterns.
Detailed definition
This metric represents the total revenue generated from the global sales of Norvasc, a branded calcium channel blocker u...
Peer comparison
Comparable to revenue metrics for legacy or off-patent branded drugs reported by other large-cap pharmaceutical companies with established product portfolios.
vtrs_segment_norvasc_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $209.80M | $198.40M | $188.80M | $207.80M | $203.00M | $189.30M | $175.00M | $202.70M | $182.40M | $175.50M | $171.80M | $176.30M | $161.90M | $168.90M | $166.20M | $172.30M | $182.70M | $179.70M | $175.20M | $210.00M |
| QoQ Change | — | -5.4% | -4.8% | +10.1% | -2.3% | -6.7% | -7.6% | +15.8% | -10.0% | -3.8% | -2.1% | +2.6% | -8.2% | +4.3% | -1.6% | +3.7% | +6.0% | -1.6% | -2.5% | +19.9% |
| YoY Change | — | — | — | — | -3.2% | -4.6% | -7.3% | -2.5% | -10.1% | -7.3% | -1.8% | -13.0% | -11.2% | -3.8% | -3.3% | -2.3% | +12.8% | +6.4% | +5.4% | +21.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's norvasc — net sales?
- Viatris (VTRS) reported norvasc — net sales of $210.00M in Q1 2026.
- How has Viatris's norvasc — net sales changed year-over-year?
- Viatris's norvasc — net sales increased by 21.9% year-over-year, from $172.30M to $210.00M.
- What is the long-term trend for Viatris's norvasc — net sales?
- Over 4 years (2021 to 2025), Viatris's norvasc — net sales has grown at a -3.7% compound annual growth rate (CAGR), from $824.70M to $709.90M.
- What does norvasc — net sales mean?
- The total revenue earned from the global sales of the branded hypertension medication Norvasc.